Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.86% | -13.83% | -39.36% | 8.03% | -7.59% |
| Total Depreciation and Amortization | 18.49% | 32.00% | 1.39% | 0.13% | 1.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.45% | -47.00% | 78.09% | 48.33% | -15.49% |
| Change in Net Operating Assets | -273.49% | 137.64% | -255.01% | 145.26% | 135.64% |
| Cash from Operations | -30.18% | 89.20% | -60.33% | 18.95% | 36.15% |
| Capital Expenditure | -3.22% | -24.56% | 42.09% | -38.91% | 1.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 26.22% | 99.17% | -98,890.00% | 63.64% | -83.33% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,175.00% | 90.55% | 37.75% | -317.02% | 288.00% |
| Cash from Investing | 42.79% | 96.69% | -2,126.07% | -99.78% | 21.48% |
| Total Debt Issued | -316.13% | -99.84% | 994,450.00% | -- | -100.00% |
| Total Debt Repaid | 5.12% | 0.78% | -1,866.67% | 85.40% | -2,800.00% |
| Issuance of Common Stock | 3,233.33% | -97.41% | 2,220.00% | -92.75% | 97.14% |
| Repurchase of Common Stock | 98.95% | -480.56% | 40.40% | 0.98% | -4,983.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.73% | -0.36% | -6.60% | 0.10% | -0.19% |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 31.64% | -120.32% | 1,339.30% | 20.63% | -60.44% |
| Foreign Exchange rate Adjustments | -75.00% | 117.39% | -483.33% | 160.00% | -119.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 38.08% | 1.16% | -270.03% | 80.54% | 33.65% |